Skip to content

A Study on the Effect of Conjugated Lionleic Acid Supplementation on Body Weight loss

A Study on the Effect of Conjugated Lionleic Acid Supplementation on Body Composition, Blood Glucose, Serum Insulin, Serum Leptin and Lipid Profile in Obese Adults (18-45) of both genders

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014052413678N2
Enrollment
60
Registered
2014-08-26
Start date
2014-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Obesity, unspecified

Interventions

Intervention 1: After collecting the initial data,The case group will received daily amount of 3 g CLA (three 1000 mg soft gels) Three times a day Before main Meals for 3 Months. Intervention 2: The c
Placebo
Treatment - Drugs
After collecting the initial data,The case group will received daily amount of 3 g CLA (three 1000 mg soft gels) Three times a day Before main Meals for 3 Months.
The control group will received a daily amount of1/5 gr placebo (three 500 mg soft gel containing paraffin oil)three times a day before main meals for three months.

Sponsors

Urmia University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
75 Years to 48 Years

Inclusion criteria

Inclusion criteria: obese adults of both genders (18-45) with a BMI given as 30-34.9 kg/m2?No weight loss or gain over 2 kg in the recent three months?the samples should have no record of diabetes?cariad disorders?record of angina pectoris, myocardial infarction, cerebral stroke, suffering from renal and hepatic diseases? chronic inflammatory diseases? thyroid diseases and gastroenterological diseases? not consuming hypoglycemic medicines? blood-pressure lowering drugs or anti blood presure medicines? beta blockers? steregene? porgesterone? not consuming any kinds of supplementations such as antioxidant vitamines? minerals? Omega 3 and CLA within two months prior to commencement of study? smoking? using alchoholic drinks? no respiratory or joint complications? not being pregnant or breastfeeding and having no intention for getting pregnant. Moreover, the samples suffering from specific complications such as epigasteric pains will be exclued from this study? The female samples will be excluded from this project in case of pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Age. Timepoint: Before Intervention. Method of measurement: Life years from birth based on birth certificate card.;Sex. Timepoint: Before Intervention. Method of measurement: with questionnaire.;Weight. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Kg/scale.;Height. Timepoint: Before Intervention. Method of measurement: Meter/ribor meter.;BMI. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Ratio of weight (kg) to height square (m).;FM%. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Percentage/Body Analyzer.;FFM%. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Percentage/Body Analyzer.;FBS. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Mg/dl/enzymatic method.;Cholesterol. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Mg/dl/enzymatic method.;TG. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Mg/dl/enzymatic method.;VLDL. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Mg/dl/enzymatic method.;LDL. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Mg/dl/enzymatic method.;HDL. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Mg/dl/enzymatic method.;Leptin. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Mg/dl /ELIZA.;Waist Size. Timepoint: Before Intervention and three months after Intervention. Method of measurement: Cm/ribbon meter.;Insulin Resistance. Timepoint: Before Intervention and three months after Intervention. Method of measurement: HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) is the same resistance to insulin index which is calculated as follows. 405/(dl/mg) fasting gluc

Secondary

MeasureTime frame
Gastroenterological side effects. Timepoint: During Intervention. Method of measurement: Taking Report.

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026